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Abstract
Background: Antibacterial resistance in Escherichia coli iso-
lates of urinary infections, mainly to fluoroquinolones, is
emerging. The aim of our study was to identify the secular
trend of resistant E. coli isolates and to characterize the
population at risk for colonization or infections with these
organisms.
Patients and Methods: Retrospective analysis of 3,430 E.coli
first isolates of urine specimens from patients admitted to the
University Hospital Basel in 1997, 2000, 2003, and 2007.
Results: Resistance to ciprofloxacin, trimethoprim/sulfa-
methoxazole, and amoxicillin/clavulanate has increased over
the 10-year study period (from 1.8% to 15.9%, 17.4% to
21.3%, and 9.5% to 14.5%, respectively). A detailed analysis
of the 2007 data revealed that independent risk factors for
ciprofloxacin resistance were age (5.3% < 35 years of age to
21.9% in patients > 75 years; odds ratio [OR] 1.29 per
10 years, 95% confidence interval [CI] 1.15–1.45, p < 0.001)
and male gender (OR 1.59, 95% CI 1.05–2.41, p = 0.04). In
contrast, nosocomial E. coli isolates were associated with
lower odds of ciprofloxacin resistance (OR 0.51, 95% CI
0.28–0.67, p < 0.001). The frequency of resistant isolate
rates was not influenced by the clinical significance (i.e.,
colonization vs urinary tract infection, UTI) or by whether the
urine was taken from a urinary catheter. Importantly, the
increase in ciprofloxacin resistance paralleled the increase in
ciprofloxacin consumption in Switzerland (Pearson’s correla-
tion test R2= 0.998, p = 0.002). Of note, resistance was less
frequent in isolates sent in by general practitioners. However,
after adjustment for age and gender, only resistance against
amoxicillin/clavulanate was found to be less frequent
(OR 0.34, 95% CI 0.16–0.92, p = 0.03).
Conclusion: Our study reveals that resistance rates have
been increasing during the last decade. Published resistance
rates may lack information due to important differences
regarding age, gender, and probable origin of the isolates.
Empirical therapy for UTI should be guided more on indi-
vidual risk profile and local resistance data than on resistance
data banks.
Infection 2009; 37: 534–539
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Introduction
Urinary tract infections (UTIs) are a common cause of
morbidity in otherwise healthy persons and mostly affect
women [1]. Uncomplicated UTIs are treated empirically
without culturing the urine [2]. Consequently, adequate
knowledge of the regional resistance pattern of uropath-
ogens is essential.
Escherichia coli (E. coli) is the primary UTI pathogen
and responsible for 75–90% of cases in the community [3,
4]. Most of the relevant studies carried out to date refer to
hospitalized patients, and the susceptibility of E. coli
varies considerably in different parts of the world [5–9].
Trimethoprim/sulfamethoxazole (TMP/SMX) is the em-
piric treatment of choice for UTIs, if the local resistance
rate is less than 10–20% [10]. However, various studies
have demonstrated that fluoroquinolones are increasingly
used [9, 11], probably because of concerns about
increasing resistance to TMP/SMX [12]. As a result of this
increased fluoroquinolone use, resistance to this antibiotic
class also is increasing among uropathogens [8, 13, 14].
Data on host factors for colonization or infection with a
resistant E. coli strain are not conclusive. Various studies
have shown that E. coli resistance may be predicted by age
[4, 15, 16], male sex [4, 15], nosocomial infection [15], trav-
eling habits [3, 17], ethnicity [3, 18], known malignancies [19],
and previous antibiotic treatment [16, 20].
As the clinical outcome is influenced by the adequacy
of the empiric antibiotic treatment [21, 22], knowledge
about the supposed probability of a resistant E. coli strain
in a individual patient is crucial. As such, current guide-
lines based on overall cumulative antimicrobial suscepti-
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bility test data may be intrinsically limited. Given this
background, the aim of our study was to analyze the
limitations of data on cumulative resistance rates by
characterizing the population at risk for colonization or
infections with E. coli isolates resistant to the most fre-
quently prescribed antimicrobial compounds. We also




The University Hospital Basel is a tertiary care center with 780
beds serving approximately 27,000 admissions annually. All
E. coli isolates grown from urine specimens in our microbiolog-
ical laboratory in 1997, 2000, 2003, and 2007 were included in our
study as being representative of the trend over the last 10 years.
The patients were either in- or out-patients of the University
Hospital Basel. Additionally, in 2007, isolates from urine speci-
mens sent by general practitioners (n = 106) were analyzed.
For susceptibility testing and the yearly cumulative antimi-
crobial susceptibility test data, the microbiology laboratory fol-
lowed the yearly updated Clinical and Laboratory Standards
Institute (CLSI) guidelines [23]. Intermediate and resistant iso-
lates were combined into one interpretative category (resistant).
The study was approved by the Ethics Committee of the Cantons
Basel-Stadt and Basel-Land (EKBB).
Secular Trends in Antimicrobial Resistance
The susceptibility patterns of all E. coli first isolates of urine
specimens from patients treated in 1997, 2000, 2003, and 2007
against the antimicrobial compounds most frequently used in the
setting of UTIs were analyzed: amoxicillin/clavulanate, TMP/
SMX, ciprofloxacin, and nitrofurantoin. The IMS HEALTH
(Hergiswil, Switzerland), an international supplier of informa-
tion and services for the pharmaceutical and health industry,
provided data on ciprofloxacin, amoxicillin/clavulanate, and
TMP/SMX use in Switzerland in terms of the number of pack-
ages sold annually.
Characteristics of Patients with E. coli Urinary
Isolates in 2007
We compiled data on the clinical background and the origin of
the 2007 isolates. Based on patient files, we distinguished
asymptomatic bacteriuria or colonization from symptomatic UTI
or urosepsis. A UTI was diagnosed if an infection was mentioned
in the charts and/or the patient was treated accordingly. Uro-
sepsis was defined if a UTI was diagnosed in combination with
the diagnosis of sepsis according to the physician(s) in charge. In
addition, urine isolates from spontaneous micturition or single-
catheterism were compared to isolates from urinary catheters. If
the culture was taken more than 48 h after admission, the isolate
was defined as being nosocomially acquired.
Statistical Analysis
For the univariate analysis, the v2-test for binary data and the
Mann–Whitney U-test for continuous data were used. Multi-
variate analysis was performed using logistic regression. The
results are reported using odds ratios (OR) and 95% confidence
intervals (95% CI). To evaluate the trend of emergence of
resistance over time, the v2-test for trend was used. To correlate
the emergence of resistance and the increase in antibiotic use, we
used Pearson’s correlation test.
Results
Secular Trends in Antimicrobial Resistance
In the years of interest, i.e., 1997, 2000, 2003, and 2007, a total
of 3,430 first isolates of E. coli from urine cultures were re-
corded. The median age of the patients was 65, 64, 63, and 72
years, respectively, and the percentage of females was
Figure 1. Development of
resistance and ciprofloxacin use
over a 10-year period in 3,430
urinary first isolates of E. coli.
Asterisk: p-values using the
v2-test for trend.
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80.4%, 82.5%, 84.0%, and 79.5%, respectively. There was a
statistically significant increase in resistance over time for all
of the antibiotics investigated with the exception of nitrofu-
rantoin (Figure 1). Notably, a major increase was observed
for ciprofloxacin (overall from 1.8% to 15.9%), which cor-
relates significantly with the increase in ciprofloxacin usage
in Switzerland (Pearson’s correlation test R2 = 0.998,
p = 0.002). A similar trend was observed for amoxicillin/
clavulanate R2 = 0.926, p = 0.074). In contrast, there was an
inverse correlation for TMP/SMX resistance and use of
TMP/SMX R2 = –0.989, p = 0.011): Despite a steady
reduction in the number of packages sold annually since
1990, we found that resistance rates had increased since 1997.
It is notable that ciprofloxacin-resistant isolates were
slightly more common in females in 1997 (Figure 2) but that
over time, the increase in ciprofloxacin resistance was more
prominent in males. A linear increase in the number of E. coli
isolates resistant to ciprofloxacin was observed with increas-
ing age from the year 2003 onwards, reaching a prevalence of
5.3% in patients younger than 35 years to 21.9% in those older
than 75 years (p < 0.001) in 2007 (Figure 3). In patients older
than 75 years, the resistance against ciprofloxacin was even
more frequent than that against TMP/SMX (Figure 3). For
amoxicillin/clavulanate, the resistance of E. coli varied in the
different age groups, with a trend to a higher resistance rate in
older patients. Nitrofurantoin resistance was found to be be-
low 10% in patients of all age groups. Among the 335 cipro-
floxacin-resistant strains analyzed in this study, 171 (51%)
were co-resistant against TMP/SMX.
Characteristics of Patients Treated in 2007 with
E. coli Isolates in Urine Specimens
1,100 patients treated in 2007 for whom E. coli was
identified in urinary first samples were further investi-
gated. The patient characteristics are given in table 1.
Detailed clinical information was available in 893 cases
Figure 2. Differences in development of ciprofloxacin resistance in
urinary first isolates of E. coli in male and female patients.
Patient age in years (n = number of isolates)
86+ 
(n = 156)
76 - 85 
(n = 305)
66 - 75 
(n = 242)
56 - 65 
(n = 118)
46 - 55 
(n = 92)
36 - 45 
(n = 73)






















Ciprofloxacin resistanceFigure 3. Age dependence of
resistance rates in E. coli first
isolates in urine specimens of
patients treated in 2007.
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(81.2% of isolates). Most patients presented with UTI,
with a minority of patients (70, 7.8%) presenting with an
urosepsis. In nine patients we found other diagnoses that
may explain a positive urine culture (Table 1). Of the
1,100 isolates 16 (1.5%) were identified as E. coli pro-
ducing extended spectrum betalactamase (ESBL).
Uni-and Multivariate Analysis of Isolates From
Patients Treated in 2007
The multivariate analysis showed that increasing age,
male gender, and a community acquirement of E. coli are
independent risk factors for resistance to ciprofloxacin
(Table 2). The rate of resistant isolates was not influenced
by the clinical significance (i.e., colonization vs UTI) or by
whether the urine was taken from a urinary catheter.
Isolates of uncomplicated UTI, which usually pre-
sented in women 40 years of age or younger (n = 48),
showed resistance rates of 4.2% to ciprofloxacin, 20.8% to
TMP/SMX, 10.4% to amoxicillin/clavulanate, and 8.3% to
nitrofurantoin.
In 2007, a total of 106/1,100 (9.9%) E. coli urinary first
isolates were sent by general practitioners to the micro-
biology laboratory. Interestingly, the resistance rates were
lower in these specimens compared to the overall data for
ciprofloxacin (5.7% vs 15.9% overall), TMP/SMX (16.0%
vs 21.3%), amoxicillin/clavulanate (5.7% vs 14.5%), and
nitrofurantoin (3.8% vs 5.3%). The difference was sig-
nificant for ciprofloxacin (OR 0.29, 95% CI 0.13–0.68,
p = 0.002) and amoxicillin/clavulanate (OR 0.33, 95% CI
0.14–0.76, p = 0.006) in the univariate analysis. However,
after adjustment for age and sex, the difference was solely
significant for amoxicillin/clavulanate (OR 0.34, 95% CI
0.16–0.92, p = 0.03).
Discussion
Our study of 3,430 urinary first isolates of E. coli shows a
trend of increasing resistance from 1997 to 2007, chiefly for
ciprofloxacin, which parallels the increase in ciprofloxacin
consumption in Switzerland. Our data indicate that the
overall cumulative susceptibility data should be adjusted
for age and gender if used as a basis for recommendations
of the empirical antimicrobial therapy for UTIs.
Secular Trends of Antimicrobial Resistance
We observed an increase in ciprofloxacin resistance from
1.8% to 15.9% within 10 years, which is similar to that
reported by other European countries [24] and the USA
[15]. The increase in ciprofloxacin resistance correlates
closely with increased ciprofloxacin consumption in
Switzerland, as previously shown in the ECO-SENS study
for other countries [25]. Although antibiotic use in Swit-
zerland is generally low in comparison with other Euro-
pean nations, Switzerland is one of the leading nations in
fluoroquinolone consumption (1.8 defined daily doses/day
per 1,000 inhabitants) [26, 27], which may explain the
rather high resistance rates for ciprofloxacin that we found
in our study.
In contrast to fluoroquinolones, there was an inverse
correlation between the number of TMP/SMX packages
sold and resistance over time. As recently speculated for
Moraxella catarrhalis and Haemophilus influenzae [28],
the selection of TMP/SMX-resistant strains may be caused
by co-resistance. This hypothesis was corroborated by the
high rate (51%) of co-resistance against TMP/SMX in
ciprofloxacin-resistant isolates in our study.
Table 1
Characteristics of the 1,100 patients in 2007 who provided
urinary E. coli first isolates.
Characteristics Values
Female gender, n (%) 874 (79.5)
Age, median (IQR) 72 (55–82)
Origin of isolate, n (%)
Spontaneous micturition or one-time 912 (82.9)
catheterization
Urinary catheter 188 (17.1)
Nosocomial isolate 323 (29.4)
Diagnosis available, n (%) 893 (81.2)
Asymptomatic bacteriuria 269 (30.1)
Urinary tract infection 545 (61.0)
Urosepsis 70 (7.8)
Other infectionsa 9 (1.0)
IQR: Interquartile range; aOther infections were one case of
prostate abscess with E. coli, four cases of epididymitis, two cases of
acute and one case of chronic prostatitis, and one case of pouchitis
Table 2
Uni- and multivariate analysis of risk factors for ciprofloxacin resistance in 1,100 urinary first isolates of E. coli in 2007.
Variable Crude OR (95% CI) p-value Adjusted OR (95% CI) p-value
Male gender 1.47 (1.02–2.22) 0.04 1.59 (1.05–2.41) 0.03
Age (+10 years) 1.32 (1.19–1.46) < 0.001 1.29 (1.15–1.45) < 0.001
Nosocomial isolate 0.51 (0.34–0.76) < 0.001 0.44 (0.28–0.67) < 0.001
Urinary catheter 1.15 (0.76–1.75) 0.50 1.21 (0.76–1.91) 0.42
Asymptomatic bacteriuria or colonization 1.03 (0.70–1.50) 0.90 1.04 (0.70–1.54) 0.85
OR: Odds ratio; CI: confidence interval
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Characteristics of Patients with E. coli Urinary
Isolates in 2007
In line with results reported in earlier studies [8, 15], we
found that ciprofloxacin resistance increased with the age
of the patient, from 5.3% in those younger than 35 years
of age to 21.9% in patients older than 75 years. In con-
trast, the resistance rate for TMP/SMX decreased with
age. It is likely that older patients with UTIs were pri-
marily treated with fluoroquinolones in recent years be-
cause the treating physicians falsely assumed that in the
elderly TMP/SMX resistance is most frequent.
Our finding that ciprofloxacin resistance is more
prevalent in males than in females confirms a recent re-
port [15]. This may be explained by the different nature of
UTIs in males with only complicated UTIs by definition
resulting in fluoroquinolone therapy.
In contrast to other pathogens, fluoroquinolone
resistance has not been reported to be higher in in-hos-
pital isolates [7, 29], which may be explained by the
widespread use of fluoroquinolones in the out-patient
settings. Nosocomial E. coli UTIs are mainly due to fac-
tors associated with the hospital setting, such as the
placement of urinary catheters during elective surgery.
Although fluoroquinolone consumption is high in Swit-
zerland, the consumption – and therefore the selective
pressure – at our hospital is rather low (2008: 6.4 defined
daily doses/100 patient days), which may explain the
comparably low fluoroquinolone resistance in nosocomial
isolates in our study. Similarly, E. coli isolates from urine
specimens sent by general practitioners were less fre-
quently resistant against ciprofloxacin and amoxicillin/
clavulanate. However, after adjustment for age and sex,
this difference disappeared as patients with UTIs seen by
general practitioners are generally younger and more
frequently female. Taken together, cumulative antimi-
crobial susceptibility test data published by microbiology
laboratories using hospital data is not necessarily accurate
for the situation met by general practitioners.
Clinical information is lacking in most of the large
epidemiological studies that have been published on the
susceptibility rates of E. coli [7, 14, 15, 19]. In contrast to
other studies [8, 30], we did not find differences in the
resistance pattern of E. coli isolates from patients pre-
senting with a UTI compared to those with colonization.
In summary, the main limitation in the use of cumu-
lative resistance data for establishing guidelines for
empirical antibiotic treatment of UTIs is age. Based on
our overall cumulative susceptibility test data, TMP/SMX
should not be used empirically, as the resistance rate is
higher than 20%. However, our study does reveal that
TMP/SMX may be used in patients in the over-75 age
group (resistance rate 18%). In contrast, ciprofloxacin can
be safely used in patients younger than 55 years of age
(resistance rate below 10%), although the overall cumu-
lative resistance rate was 19%.
There are some limitations to our study. Due to its
retrospective character, certain information, such as pre-
vious antibiotic treatment(s), could not be obtained. Only
a small and possibly not sufficiently representative num-
ber of isolates originating from patients of general prac-
titioners were available. A selection bias of patients
presenting with more severe infections is likely because
the samples were not prospectively taken. The definition
of ‘nosocomial’ was limited by the lack of knowledge of
hospitalization at other institutions before admission to
our hospital. Furthermore, the time from application of a
urinary catheter up to the time of urinary culture was
unknown. Another limitation is that data on the amount
of ciprofloxacin use were available only as the number of
packages sold annually, but defined daily doses, as sug-
gested by the World Health Organization, would probably
be more accurate.
Conclusion
Resistance in urinary isolates of E. coli is emerging,
chiefly for ciprofloxacin, and reflects the increased use of
antimicrobial compounds. Cumulative resistance rates
and surveillance networks may not predict E. coli resis-
tance on an individual level because they are limited by
the important differences in resistance rates with regard to
age and gender. Therefore, guidelines for empirical ther-
apy of UTI should be based on a knowledge of individu-
alized resistance that takes – minimally – age and gender
into consideration.
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